Abstract Library

#3084 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): A Case Report and Review of Literature

Introduction: Majority of euroendocrine tumorsare found in the gastrointestinal tract and bronchopulmonary. Multifocal disease is common among patients with low-grade NET. One example of this is diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. DIPNECH is an extremely rare but indolent disease with predilection for nonsmoking, middle-aged women.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cruz M

Authors: Cruz M,

Keywords: DIPNECH, Neuroendocrine tumor, carcinoid,

#3048 Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors

Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Schinzari G, Maiorano B, Rossi E, Bianchi A, Chiloiro S,

Keywords: pNET, non-functioning, sporadic, somatostatin analogs, surveillance,

#3041 Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database

Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Walter T

Authors: Walter T, Lapeyre Mestre M, Gueguen D, Bouille C, Laborey M,

Keywords: Carcinoid syndrome, resources, health economics,

#3039 Evaluation of Overall Survival (OS) in Patients with NETG1/G2 Neuroendocrine Neoplasms of the Small Intestine (SI-NENs)

Introduction: In many cases, the cause of death in patients with carcinoid syndrome (CS) is carcinoid heart disease (CHD) which is most often diagnosed in patients with SI-NEN.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ćwikła J

Authors: Konsek-Komorowska S, Pęczkowska M, Kolasińska-Ćwikła A, Cichocki A, Roszkowska-Purska K,

Keywords: Neuroendocrine Neoplasms of the Small Intestine, SI-NENs, carcinoid syndrome, carcinoid heart disease, Overall Survival,

#3013 Structurally-Optimized Peptide VMT-Alpha-NET Enhances the Efficacy of SSTR2-Targeted Alpha-Particle Therapy for Neuroendocrine Tumors

Introduction: 203Pb/212Pb is a promising theranostics pair for SSTR2-targeted alpha-particle therapy for neuroendocrine tumors (NETs). The development of SSTR2-targeted peptides that are optimized for the Pb isotopes has the potential to improve performance.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Lee D, Li M, Baumhover N, Liu D, Sagastume E,

Keywords: prrt, VMT-alpha-NET, 203Pb/212Pb theranostics,